Latest Breaking News On - Brain metastases - Page 2 : comparemela.com

Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint

Zai Lab (ZLAB) Partner Novocure (NVCR) Announces METIS Phase 3 Clinical Trial Met Primary Endpoint
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Zai labZai lab limited nasdaqZai lab limitedTumor treating fieldsGreater chinaBrain metastases

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with.

United statesZai lab limited nasdaqZai labExchange commissionZai lab forwardZai lab limitedTumor treating fieldsGreater chinaBrain metastasesChinese journalTreating fieldsPrivate securities litigation reform act

TTFields Meets Time to Intracranial Progression End Point in NSCLC Brain Metastases

TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.

United statesAsaf danzigerMinesh mehtaRadiation oncologyBaptist health miami cancer instituteTumor treating fieldsLung cancerNon small cell lung cancerBrain metastasesLung cancer brain metastases

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on.

New south walesUnited statesJonathan yangJohn friendDrug administrationKazia therapeutics limitedPrnewswire kazia therapeutics limitedExchange commissionDepartment of radiation oncologyAmerican society for clinical oncologySociety for neuroUniversity of washington school medicineKazia therapeuticsTreating patientsPathway mutation brainTherapeutics limited

Advanced melanoma survival rates improve significantly from 2013 to 2019, Dutch study finds

The change in overall survival (OS) among advanced melanoma patients diagnosed between 2013 and 2021.

United statesThe netherlandsAmerican joint committee on cancerCytotoxict lymphocyte antigenProgrammed cell deathMitogen activated protein kinaseLymphocyte activation geneTumor infiltrating lymphocyteDutch melanoma treatment registryAmerican joint committeeBrain metastasesEll deathCtla 4Programmed cell death